Literature DB >> 32798339

Appraisal of Critically Ill COVID-19 Patients at a Dedicated COVID Hospital.

Rakesh Bhadade1, Minal Harde2, Rosemarie deSouza3, Abhiram Kasbe4, Charulata Deshpande5, Sona Dave6, Mohan Joshi7, Ramesh Bharmal8, Tushar Madke9.   

Abstract

PURPOSE: To study the pattern of severe COVID-19 to reduce morbidity and mortality.
METHODS: It was an observational cohort study for comprehensive clinical analysis of critically ill COVID-19 patients at a dedicated COVID public hospital.
RESULTS: Total 373(13.6%) patients were critically ill with 254(68.1%) males and 119(31.9%) females (including 25 pregnant) and death occurred in 69(18.5%) patients. Mean of parameters associated with critical COVID illness and having significant difference among dead and recovered were; age (47.08,p= 5.67E- 09), SpO2 (86.08), blood sugar(168.47,p= 1.86E-08), IL-6(210.5,p=0.0058) D-dimer(0.753,p= 0.00178). All the patients were given oxygen by non invasive technique, in 46(12.3%) intubation and invasive ventilation required. Use of hydroxychloroquin in 284(76.1%) (p=0.041,OR0.555,95%CI 0.314-0.981), lopinavir/ ritonavir in 283(75.9%) (p=4.222E-009,OR0.198, 95%CI0.114-0.345), tocilizumab in 124(33.2%) patients, (p=3.27E006, OR0.150, 95%CI0.063-0.358) were associated with recovery. Factors that influenced mortality were presence of co-morbidities (p=0.088,OR1.784,95%CI0.911-3.492), hypertension(p=0.0031,OR2.432,95% CI1.370 -4.318), low SpO2 (p=3.91E-010,OR0.017,95%CI0.002-0.137), high blood sugar(p=7.75E-009,OR8.514,95%CI 3.776-19.201), high LDH(p=0.00064,OR2.7 22,95%CI1.545-4.798) high ferritin(p=0.00014,OR4.606,95%CI 2.035-10.422), high D-dimer(p=2.85E-007,OR4.090,95%CI 2.371-7.056), low PFR(p=4.84E-008), and endotracheal intubation(p=3.14E-043,OR165.936,95%CI48.160-571.731). Using binary logistic regression, elevated IL-6(0.02441), low PFR(0.00082), and endotracheal intubation(2.04E-10) were statistically significant predictors of death.
CONCLUSION: "Happy Hypoxia", hyperglycemia, high inflammatory markers (IL-6, ferritin), and ARDS were hallmark of critical COVID-19, early detection of factors associated with severity and mortality and starting the multipronged management with oxygen in prone position, hydroxychloroquin, antiviral, methylprednisolone, anticoagulants, tocilizumab early may help in halting the worsening of COVID and reduce morbidity and mortality. © Journal of the Association of Physicians of India 2011.

Entities:  

Mesh:

Year:  2020        PMID: 32798339

Source DB:  PubMed          Journal:  J Assoc Physicians India        ISSN: 0004-5772


  5 in total

1.  Laboratory biomarker predictors for disease progression and outcome among Egyptian COVID-19 patients.

Authors:  Lamiaa A Fathalla; Lamyaa M Kamal; Omina Salaheldin; Mahmoud A Khalil; Mahmoud M Kamel; Hagar H Fahim; Youssef As Abdel-Moneim; Jawaher A Abdulhakim; Ahmed S Abdel-Moneim; Yomna M El-Meligui
Journal:  Int J Immunopathol Pharmacol       Date:  2022 Jan-Dec       Impact factor: 3.298

2.  Clinical Characteristics and Outcome of Patients With Severe COVID-19 Pneumonia at a Public Sector Hospital in Karachi, Pakistan.

Authors:  Shehla Baqi; Arshi Naz; Muneeba Ahsan Sayeed; Samita Khan; Humera Ismail; Vijai Kumar; Hiranand Somjimal; Jahangir Aneela; Sidra Imtiaz; Sadqa Aftab
Journal:  Cureus       Date:  2021-02-03

Review 3.  The Association between TNF-α, IL-6, and Vitamin D Levels and COVID-19 Severity and Mortality: A Systematic Review and Meta-Analysis.

Authors:  Ceria Halim; Audrey Fabianisa Mirza; Mutiara Indah Sari
Journal:  Pathogens       Date:  2022-02-01

4.  Acute Kidney Injury in COVID-19: Clinical Profile and Outcome.

Authors:  Jyoti Bansode; Salman Ali Sayed; Shakir Ahmad; Smriti Sinha; Rudramani Swami; Kalpana Mehta
Journal:  Indian J Nephrol       Date:  2022-05-07

5.  Neutrophil-Lymphocyte Ratio in Patients with COVID-19 as a Simple Tool to Predict Requirement of Admission to a Critical Care Unit.

Authors:  Sagar S Maddani; Nitin Gupta; Shashikiran Umakanth; Sowmya Joylin; Kavitha Saravu
Journal:  Indian J Crit Care Med       Date:  2021-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.